R. Maclean

发表

A pilot study of feasibility and efficacy of telemedicine-delivered psychophysiological treatment for vascular headache.

K. Meador, Trishul Devineni, J. Arena, 2004, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.

Patterns of Care and Treatment Target Success among Persons with Type 2 Diabetes Mellitus in Dubai: A Retrospective Cohort Study.

A. Levy, S. Szabo, R. Maclean, 2015, Value in Health Regional Issues.

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

P. Rahman, B. Haraoui, C. Thorne, 2009, Clinical Rheumatology.

Quality of Care for Patients with Type 2 Diabetes Mellitus in Dubai: A HEDIS-Like Assessment

A. Levy, S. Szabo, R. Maclean, 2015, International journal of endocrinology.

Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States

R. Maclean, Yong Yuan, L. Rosenblatt, 2010, Journal of medical economics.

Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis.

P. Tugwell, Tracy T Li, G. Wells, 2007, The Journal of rheumatology.

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.

G. Oster, F. Wolfe, N. Shadick, 2008, Journal of Rheumatology.

The Observational Evaluation of Subjective Well‐Being in Patients with Rheumatoid Arthritis

M. Seligman, Nansook Park, C. Peterson, 2009 .

Proposed Severity and Response Criteria for Routine Assessment of Patient Index Data (RAPID3): Results for Categories of Disease Activity and Response Criteria in Abatacept Clinical Trials

T. Pincus, M. Bergman, R. Maclean, 2011, The Journal of Rheumatology.

The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative Colitis

R. Goetzel, R. Ozminkowski, Shaohung S. Wang, 2008, Journal of occupational and environmental medicine.

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.

G. Oster, F. Wolfe, N. Shadick, 2007, Rheumatology.

Systematic review of studies of productivity loss due to rheumatoid arthritis.

W. Burton, E. Ruderman, A. Morrison, 2006, Occupational medicine.

Item Response Theory Methods can Improve the Measurement of Physical Function by Combining the Modified Health Assessment Questionnaire and the SF-36 Physical Function Scale

J. Ware, M. Kosinski, R. Maclean, 2006, Quality of Life Research.

Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology "vital signs" for usual clinical care.

T. Pincus, M. Bergman, R. Maclean, 2009, Rheumatic diseases clinics of North America.

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.

T. Pincus, M. Bergman, K. Raghupathi, 2007, Rheumatology.

Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity, rather than traditional research.

T. Pincus, R. Maclean, Y. Yazici, 2007, Clinical and experimental rheumatology.

A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ).

T. Pincus, M. Bergman, R. Maclean, 2007, Best practice & research. Clinical rheumatology.

Value-based insurance design: benefits beyond cost and utilization.

A. Fendrick, M. Chernew, T. Gibson, 2015, The American journal of managed care.

Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis

P. Tugwell, P. Tugwell, G. Wells, 2007, Annals of the rheumatic diseases.

Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.

G. L’italien, A. Pikalov, Y. Jing, 2009, Clinical therapeutics.

Value of survival gains in chronic myeloid leukemia.

J. Penrod, Wesley Yin, D. Lakdawalla, 2012, The American journal of managed care.

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

P. Emery, J. Cole, A. Russell, 2006, Annals of the rheumatic diseases.

Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept.

R. Maclean, G. Wallenstein, T. Li, 2008, Rheumatology.

The Impact of Rheumatoid Arthritis on Medical Expenditures, Absenteeism, and Short-Term Disability Benefits

R. Goetzel, R. Ozminkowski, Shaohung S. Wang, 2006, Journal of occupational and environmental medicine.

The Direct and Indirect Cost Burden of AcuteCoronary Syndrome

R. Goetzel, S. Johnston, W. Burton, 2011, Journal of Occupational and Environmental Medicine.

Peripheral arterial disease and renal transplantation.

B. Kasiske, J. Snyder, R. Maclean, 2006, Journal of the American Society of Nephrology : JASN.

Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.

M. Beers, D. Fick, J. Waller, 2003, Archives of internal medicine.

Productivity cost model of the treatment of rheumatoid arthritis with abatacept

R. Marioni, W. Burton, A. Morrison, 2008, Journal of medical economics.

Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia.

G. Joyce, D. Goldman, D. Lakdawalla, 2012, The American journal of managed care.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

R. Westhovens, J. Cole, Y. Sherrer, 2006, Rheumatology.

More to gain: dietary energy density is related to smoking status in US adults

R. MacLean, J. Vernarelli, R. Maclean, 2018, BMC Public Health.

Focus group data as a tool in assessing effectiveness of a hand hygiene campaign.

K. Woeltje, M. Hawkins, R. Maclean, 2005, American journal of infection control.

The effect of explicit financial incentives on physician behavior.

B. Armour, J. Etchason, M. Pitts, 2001, Archives of internal medicine.

Development and validation of a short form of the valued life activities disability questionnaire for rheumatoid arthritis

S. Buyske, D. Allen, P. Katz, 2011, Arthritis care & research.

AMCP Partnership Forum: Improving Quality, Value, and Outcomes with Patient-Reported Outcomes

D. Nilasena, F. Kalush, A. Duhig, 2018, Journal of managed care & specialty pharmacy.

Patient Commitment to Health (PACT-Health) in the Heart Failure Population: A Focus Group Study of an Active Communication Framework for Patient-Centered Health Behavior Change

Katherine K. Kim, J. Doctor, D. Meeker, 2019, Journal of medical Internet research.

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.

G. Oster, F. Wolfe, N. Shadick, 2007, Rheumatology.

Group dynamics in telemedicine-delivered and standard multidisciplinary team meetings: results from the TELEMAM randomised trial

John Cairns, Ross Maclean, Guy Fielding, 2006 .

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.

G. Oster, F. Wolfe, N. Shadick, 2008, The Journal of rheumatology.